Changes for page Customer segments in Health and Wellbeing Living Labs
Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.7
edited by Sarantis Dimitriadis
on 2022/06/02 10:56
on 2022/06/02 10:56
Change comment:
There is no comment for this version
To version 6.1
edited by Sarantis Dimitriadis
on 2023/05/30 09:33
on 2023/05/30 09:33
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -7,6 +7,8 @@ 7 7 (% class="western" lang="en-GB" style="text-align:justify" %) 8 8 (% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following: 9 9 10 +: 11 + 10 10 * ((( 11 11 (% lang="en-US" %)**Non-professional end users:** 12 12 ... ... @@ -15,6 +15,8 @@ 15 15 * (% lang="en-US" %)**Public health and social service clients: **Those who use public services. 16 16 ))) 17 17 20 +: 21 + 18 18 * ((( 19 19 (% lang="en-US" %)**Professional end users** 20 20 ... ... @@ -25,9 +25,13 @@ 25 25 * (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level. 26 26 ))) 27 27 32 +: 33 + 28 28 (% class="western" lang="en-GB" %) 29 29 (% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows: 30 30 37 +: 38 + 31 31 * ((( 32 32 (% lang="en-US" %)**Private sector organizations: **(business developers and researchers) 33 33 ... ... @@ -42,6 +42,8 @@ 42 42 * (% lang="en-US" %)Pharmaceutical companies 43 43 ))) 44 44 53 +: 54 + 45 45 * ((( 46 46 (% lang="en-GB" %) 47 47 (% lang="en-US" %)**Public sector organizations:** ... ... @@ -57,6 +57,8 @@ 57 57 * (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process. 58 58 ))) 59 59 70 +: 71 + 60 60 * ((( 61 61 (% lang="en-GB" %) 62 62 (% lang="en-US" %)**Education and research organizations:** ... ... @@ -70,6 +70,8 @@ 70 70 * (% lang="en-US" %)**Private research organizations** such as technology and innovation centers 71 71 ))) 72 72 85 +: 86 + 73 73 * ((( 74 74 (% lang="en-GB" %) 75 75 (% lang="en-US" %)**Civil society organizations:** ... ... @@ -77,6 +77,8 @@ 77 77 * (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level. 78 78 ))) 79 79 94 +: 95 + 80 80 * ((( 81 81 (% lang="en-GB" %) 82 82 (% lang="en-US" %)**Networks and clusters:** ... ... @@ -84,241 +84,89 @@ 84 84 * (% lang="en-US" %)Company cluster organizations and company networks 85 85 * (% lang="en-US" %)International, national, regional and local networks 86 86 ))) 87 - 88 88 89 -(% class="western" lang="en-GB" %) 90 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table . 104 +: 91 91 92 -(% cellspacing="0" style="border-collapse:collapse; margin-left:auto; margin-right:auto" %) 93 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 94 -(% class="western" lang="en-GB" style="text-align:center" %) 95 -(% lang="en-US" %)**Age or age group** 96 -))) 97 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:11px; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 98 98 (% class="western" lang="en-GB" %) 107 +(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in the following table . 108 + 109 +(% style="height:1004px; margin-left:auto; margin-right:auto; width:1694px" %) 110 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)**Age groups** 111 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 99 99 (% lang="en-US" %)Specific age range 100 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 101 -(% class="western" %) 113 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 102 102 103 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)(((115 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 104 104 (% class="western" %) 105 105 106 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:152px" %)(((118 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:152px" %)((( 107 107 (% class="western" %) 108 108 109 109 ))) 110 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 111 -(% class="western" lang="en-GB" %) 112 -(% lang="en-US" %)Elderly 113 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 114 -(% class="western" lang="en-GB" %) 115 -(% lang="en-US" %)Adults 116 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 117 -(% class="western" lang="en-GB" %) 118 -(% lang="en-US" %)Youth 119 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:justify; vertical-align:middle; width:152px" %)((( 120 -(% class="western" lang="en-GB" %) 121 -(% lang="en-US" %)Children 122 -))) 123 -|(% colspan="4" style="border-bottom:none; border-left:none; border-right:none; border-top:none; height:12px; padding:0in; vertical-align:top; width:634px" %)((( 122 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Adolescents|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Older Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)General Population 123 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 124 124 (% class="western" %) 125 125 126 126 ))) 127 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 128 -(% class="western" lang="en-GB" style="text-align:center" %) 129 -(% lang="en-US" %)**Health status** 130 -))) 131 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; padding:0in; text-align:justify; vertical-align:middle; width:153px" %)((( 127 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adolescents Health status (disease, disorder or disability)** 128 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)((( 132 132 (% class="western" lang="en-GB" %) 133 133 (% lang="en-US" %)Healthy 134 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:justify; vertical-align:middle; width:153px" %)(((131 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 135 135 (% class="western" lang="en-GB" %) 136 - (%lang="en-US" %)Patient137 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:justify; vertical-align:middle; width:153px" %)(((133 + 134 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)((( 138 138 (% class="western" lang="en-GB" %) 139 - (%lang="en-US" %)Rehabilitant140 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:justify; vertical-align:middle; width:152px" %)(((136 + 137 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)((( 141 141 (% class="western" lang="en-GB" %) 142 - (%lang="en-US" %)Recovered/Survivor139 + 143 143 ))) 144 -|(% colspan="4" style="border- bottom:none; border-left:none; border-right:none; border-top:none; height:12px;padding:0in;vertical-align:top; width:634px" %)(((141 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 145 145 (% class="western" %) 146 146 147 147 ))) 148 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 149 -(% class="western" lang="en-GB" style="text-align:center" %) 150 -(% lang="en-US" %)**A specific disease, disorder or disability** 151 -))) 152 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 153 -(% class="western" lang="en-GB" %) 154 -(% lang="en-US" %)ADHD 155 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 156 -(% class="western" lang="en-GB" %) 157 -(% lang="en-US" %)Dementia 158 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 159 -(% class="western" lang="en-GB" %) 160 -(% lang="en-US" %)Parkinsons’ disease 161 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 162 -(% class="western" lang="en-GB" %) 163 -(% lang="en-US" %)Loneliness and Social Isolation 164 -))) 165 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:11px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 166 -(% class="western" lang="en-GB" %) 167 -(% lang="en-US" %)Autism 168 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 169 -(% class="western" lang="en-GB" %) 170 -(% lang="en-US" %)Down syndrome 171 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 172 -(% class="western" lang="en-GB" %) 173 -(% lang="en-US" %)Physical disability 174 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 175 -(% class="western" lang="en-GB" %) 176 -(% lang="en-US" %)Mental health 177 -))) 178 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 179 -(% class="western" lang="en-GB" %) 180 -(% lang="en-US" %)Cardiovascular disease 181 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 182 -(% class="western" lang="en-GB" %) 183 -(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF) 184 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 185 -(% class="western" lang="en-GB" %) 186 -(% lang="en-US" %)Sleep apnea/apnea 187 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 188 -(% class="western" lang="en-GB" %) 189 -(% lang="en-US" %)Mild cognitive impairment 190 -))) 191 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 192 -(% class="western" lang="en-GB" %) 193 -(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD) 194 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 195 -(% class="western" lang="en-GB" %) 196 -(% lang="en-US" %)Language disability 197 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 198 -(% class="western" lang="en-GB" %) 199 -(% lang="en-US" %)Substance abuse (drugs, alcohol) 200 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 201 -(% class="western" lang="en-GB" %) 202 -(% lang="en-US" %)Multiple sclerosis 203 -))) 204 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:50px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 205 -(% class="western" lang="en-GB" %) 206 -(% lang="en-US" %)Cognitive disorder (mild, major) 207 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 208 -(% class="western" lang="en-GB" %) 209 -(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation 210 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 211 -(% class="western" lang="en-GB" %) 212 -(% lang="en-US" %)Trauma patient 213 - 214 -(% class="western" lang="en-GB" %) 215 -(% lang="en-US" %)(e.g., a spinal cord injury) 216 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 217 -(% class="western" lang="en-GB" %) 218 -(% lang="en-US" %)Neurodegenerative diseases 219 -))) 220 -|(% colspan="4" style="border-bottom:none; border-left:none; border-right:none; border-top:none; height:12px; padding:0in; vertical-align:top; width:634px" %)((( 145 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adults Health status (disease, disorder or disability)** 146 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Healthy|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Schizophrenia|Multiple-Sclerosis|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Parkinson Disease 147 +|Post-Stroke Patients with Moving or Linguistic Disability|Mild Cognitive Impairment|Sleep Disorders: e.g., Apnea, Hypopnea|With Disability 148 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %) 149 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 221 221 (% class="western" %) 222 222 223 223 ))) 224 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 225 -(% class="western" lang="en-GB" style="text-align:center" %) 226 -(% lang="en-US" %)**Clients of a specific service** 227 -))) 228 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:11px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 229 -(% class="western" lang="en-GB" %) 230 -(% lang="en-US" %)Child welfare 231 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 232 -(% class="western" lang="en-GB" %) 233 -(% lang="en-US" %)Nursing home 234 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 235 -(% class="western" lang="en-GB" %) 236 -(% lang="en-US" %)Employment service 237 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 153 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Older Adults Health status (disease, disorder or disability)** 154 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Parkinson Disease|Mild Cognitive Impairment|With Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 238 238 (% class="western" %) 239 239 240 240 ))) 241 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)(((158 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 242 242 (% class="western" lang="en-GB" %) 243 - (%lang="en-US" %)Early childhood education244 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:left; vertical-align:middle; width:153px" %)(((160 + 161 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)((( 245 245 (% class="western" lang="en-GB" %) 246 -(% lang="en-US" %)Home care 247 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 248 -(% class="western" lang="en-GB" %) 249 249 250 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in;text-align:left; vertical-align:middle; width:152px" %)(((164 +)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 251 251 (% class="western" lang="en-GB" %) 252 252 253 253 ))) 254 -|(% colspan="4" style="border- bottom:none; border-left:none; border-right:none; border-top:none; height:12px;padding:0in;vertical-align:top; width:634px" %)(((168 +|(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)((( 255 255 (% class="western" %) 256 256 257 257 ))) 258 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:12px; padding:0.04in 0in; text-align:center; vertical-align:middle; width:634px" %)((( 259 -(% class="western" lang="en-GB" style="text-align:center" %) 260 -(% lang="en-US" %)**Vulnerable groups** 261 -))) 262 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:50px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 172 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**General Population Health status (disease, disorder or disability)** 173 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Ipf Patients|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Prostate Cancer|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 263 263 (% class="western" lang="en-GB" %) 264 -(% lang="en-US" %)Minors/Children 265 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 266 -(% class="western" lang="en-GB" %) 267 -(% lang="en-US" %)Single parents with minor children 268 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 269 -(% class="western" lang="en-GB" %) 270 -(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence 271 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 272 -(% class="western" lang="en-GB" %) 273 -(% lang="en-US" %)Substance users 274 - 275 -(% class="western" lang="en-GB" %) 276 -(% lang="en-US" %)(drugs, alcohol) 175 +Down Syndrome 277 277 ))) 278 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding: 0in; text-align:left; vertical-align:middle; width:153px" %)(((177 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Chronical Diseases: e.g., Persons With Chronic Pulmonary (Copd)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Cardiological Or Other Conditions (Aphasia)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Breast Cancer Survivors|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)((( 279 279 (% class="western" lang="en-GB" %) 280 -(% lang="en-US" %)Disabled people 281 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 282 -(% class="western" lang="en-GB" %) 283 -(% lang="en-US" %)Victims of trafficking in human beings 284 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 285 -(% class="western" lang="en-GB" %) 286 -(% lang="en-US" %)Ethnic minorities and immigrants 287 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 288 -(% class="western" lang="en-GB" %) 289 -(% lang="en-US" %)Isolated people 290 -))) 291 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 292 -(% class="western" lang="en-GB" %) 293 -(% lang="en-US" %)Elderly people 294 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 295 -(% class="western" lang="en-GB" %) 296 -(% lang="en-US" %)Persons with serious illnesses 297 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 298 -(% class="western" lang="en-GB" %) 299 -(% lang="en-US" %)Homeless people 300 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 301 -(% class="western" lang="en-GB" %) 302 -(% lang="en-US" %)Ex-prisoners and people with criminal background 303 -))) 304 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 305 -(% class="western" lang="en-GB" %) 306 -(% lang="en-US" %)Pregnant women 307 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 308 -(% class="western" lang="en-GB" %) 309 -(% lang="en-US" %)Persons with mental disorders 310 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:153px" %)((( 311 -(% class="western" lang="en-GB" %) 312 312 313 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; padding:0in; text-align:left; vertical-align:middle; width:152px" %)((( 314 -(% class="western" lang="en-GB" %) 315 - 316 316 ))) 317 -\\ 318 318 182 +: 319 319 320 320 (% class="western" lang="en-GB" %) 321 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .185 +(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in (%%)the table below(% style="page-break-before:always" %) . 322 322 323 323 |**Researcher expertise**|**Brief use case description** 324 324 |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making